Skip to content

News

04 October 2018

Charles Russell Speechlys advises Kreos Capital on €20 million growth capital facility in Medtech company

Charles Russell Speechlys have advised Kreos Capital on its additional growth capital facility of €20 million in Cellnovo Limited (“Cellnovo”), the wholly-owned subsidiary company of Cellnovo Group SA, a Med Tech company marketing the first mobile, connected, all-in-one diabetes management system, listed on Euronext Paris. This is a follow on facility by Kreos subsequent to its €7 million growth capital facility in 2015 and its €5 million growth capital facility in 2017.

The Charles Russell Speechlys core team comprised Chris Putt (Partner), Rossana Conti (Legal Director), Amelly Kok (Associate) and Dafni Loizou (Associate) from our Corporate Team, and Paul Kay (Partner) from our Banking Team. Foreign counsel who have advised on this transaction are Reinhart Marville Torre (French law).

TOP